These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Advances and challenges in the use of biomarkers in clinical trials. Chabner B Clin Adv Hematol Oncol; 2008 Jan; 6(1):42-3. PubMed ID: 18322440 [No Abstract] [Full Text] [Related]
4. Cancer biomarkers: current issues and future directions. Jain KK Curr Opin Mol Ther; 2007 Dec; 9(6):563-71. PubMed ID: 18041667 [TBL] [Abstract][Full Text] [Related]
5. Proteomics and translational medicine: molecular biomarkers for cancer diagnosis, prognosis and prediction of therapy outcome. Cho WC Expert Rev Proteomics; 2011 Feb; 8(1):1-4. PubMed ID: 21329422 [No Abstract] [Full Text] [Related]
6. Biomarker boom slowed by validation concerns. Benowitz S J Natl Cancer Inst; 2004 Sep; 96(18):1356-7. PubMed ID: 15367567 [No Abstract] [Full Text] [Related]
7. [Molecular genetic tumor markers and their analysis for diagnosis and therapy of cancer patients]. Ianov IuK; Novik AA; Belokhvostov AS Klin Med (Mosk); 1999; 77(11):4-9. PubMed ID: 10635622 [No Abstract] [Full Text] [Related]
8. The search for optimal response prediction in cancer leads to a personalized approach. Van Cutsem E; Ciardiello F Target Oncol; 2010 Mar; 5(1):3-4. PubMed ID: 20349283 [No Abstract] [Full Text] [Related]
9. [Molecular markers having a prognostic or therapeutic value in cancer]. Brousset P Ann Pathol; 2008 Nov; 28 Spec No 1(1):S69-70. PubMed ID: 18984307 [No Abstract] [Full Text] [Related]
10. Metabolomics in cancer: a bench-to-bedside intersection. Claudino WM; Goncalves PH; di Leo A; Philip PA; Sarkar FH Crit Rev Oncol Hematol; 2012 Oct; 84(1):1-7. PubMed ID: 22429650 [TBL] [Abstract][Full Text] [Related]
11. Biomarkers of clinical trials using molecular inhibitors and radiotherapy: state-of-the-art. Preface. Bristow RG Cancer Metastasis Rev; 2008 Sep; 27(3):337-8. PubMed ID: 18427733 [No Abstract] [Full Text] [Related]
12. [Anticancer drug dosing--pharmacogenomic biomarkers or body surface area?]. Lehne G; Bjørheim J; Saeter G Tidsskr Nor Laegeforen; 2007 Apr; 127(8):1040-4. PubMed ID: 17457389 [TBL] [Abstract][Full Text] [Related]
13. Challenges of cancer biomarker profiling. Bensalah K; Montorsi F; Shariat SF Eur Urol; 2007 Dec; 52(6):1601-9. PubMed ID: 17919807 [TBL] [Abstract][Full Text] [Related]
14. Personalized medicine for cancer: from molecular signature to therapeutic choice. Sikora K Adv Cancer Res; 2007; 96():345-69. PubMed ID: 17161685 [No Abstract] [Full Text] [Related]
15. Advances in biomarkers for targeted agents. Maitland ML Clin Adv Hematol Oncol; 2011 Sep; 9(9):688-90. PubMed ID: 22402514 [No Abstract] [Full Text] [Related]
16. Implications of salivary proteomics in drug discovery and development: a focus on cancer drug discovery. Hu S; Yen Y; Ann D; Wong DT Drug Discov Today; 2007 Nov; 12(21-22):911-6. PubMed ID: 17993408 [TBL] [Abstract][Full Text] [Related]
17. Potentially useful biomarkers for the diagnosis, treatment and prognosis of lung cancer. Cho WC Biomed Pharmacother; 2007 Oct; 61(9):515-9. PubMed ID: 17913444 [TBL] [Abstract][Full Text] [Related]